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Nonmelanoma skin cancers (NMSCs), which include basal and squamous cell cancers are the most common human cancers.
BCCs have a relatively low metastatic rate and slow growth and are frequently underreported. Whilst there is a deﬁnite role
of sunexposure in the pathogenesis of BCC, several additional complex genotypic, phenotypic and environmental factors are
contributory. The high prevalence and the frequent occurrence of multiple primary BCC in aﬀected individuals make them
an important public health problem. This has led to a substantial increase in search for newer noninvasive treatments for
BCC. Surgical excision with predetermined margins remains the mainstay treatment for most BCC. Of the newer non-invasive
treatments only photodynamic therapy and topical imiquimod have become established in the treatment of certain BCC subtypes,
while the search for other more eﬀective and tissue salvaging therapies continues. This paper focuses on the pathogenesis and
management of BCC.
1.Introduction
Basal cell carcinoma (BCC) is the commonest skin cancer in
Caucasiansanditsincidencecontinuestoincreaseworldwide
[1]. First described in 1824 by Jacob, it is a slow growing,
locallydestructive,skintumouroftheepidermis[2].Average
life time risk of developing a BCC is approximately 30% in
Caucasians, and represents a signiﬁcant public health issue
[3]. Australia has the highest incidence of BCC in world with
1383 new cases diagnosed for every 100,000 population in
2008[4].InUKthereareestimated53,000newcasesperyear,
and 153.9 cases per 100, 000 person years [5] . Figures for
incidence are likely to be signiﬁcantly underestimated in the
UK as BCCs are not routinely registered.
Fortunately in respect of the high incidence, BCCs
rarely metastasise. Metastatic rate is <0.1%, and reported
sites of metastasis are skeletal and pulmonary [6, 7]. Risk
factors for metastasis are neglect over many years, perineural
invasion,sizeover10cm2,andbasisquamousandmorphoeic
subtypes [8]. Tumours left untreated can cause extensive
tissue destruction, disﬁgurement, inﬁltrate cartilage, muscle
or bone with even intracranial extension. BCCs may also
develop in scars or sebaceous naevi and are associated with
several genetic syndromes including basal cell naevus (Gor-
lin’s) syndrome, xeroderma pigmentosa, Bazex syndrome,
and albinism [9].
ThereareseveralsubtypesofBCC:nodular,cystic,super-
ﬁcial, morphoeic (sclerosing), keratotic, pigmented, and
micronodular [10]. Nodular BCCs are the most common
in UK, though 10–40% show a mixed pattern of 2 or more
subtypes [11]. Most nodular and morphoeic subtypes are
found on the head and neck, contrasting with 46% of
superﬁcial BCC occurring over truncal sites [12].
Once a BCC is diagnosed, risk of further BCC is approx-
imately 10-fold over the general population. Risk factors for
developing further BCCs are multiple BCC at presentation,
older age at presentation, and index BCC over 1cm. BCC
arising on the trunk are usually associated with development
of further truncal BCC [10]. Overall risk of further BCC is
approximately 46% over a 10-year period [13].
2.Aetiology
Aetiology of BCC is a multifactorial combination of geno-
type, phenotype, and environmental factors. Ultraviolet2 Journal of Skin Cancer
radiation is one the most signiﬁcant factors, demonstrated
by the global highest incidence in areas closer to the equator,
whilst Finland has the lowest incidence of all European
countries. UVB irradiation directly damages cellular DNA
and RNA causing covalent bonding between adjacent pyrim-
idines, and formation of mutagenic products. UVA produces
the formation of toxic reactive oxygen species [14]. Overall
intermittent sun exposure and childhood sun exposure may
be of more importance than cumulative sun exposure [15,
16].
Several genes have been associated with BCC develop-
ment. Cytochrome 450 (CYP) and glutathione S-transferase
(GST) are both involved in detoxifying various muta-
gens. Speciﬁc polymorphisms within these supergenes have
been identiﬁed, in particular GSTM1, GSTT1, GSTP1 and
CYP2D6 [17, 18]. CYP2D6 may be associated with the
development of multiple BCCs also [19]. Basal cell naevus
syndrome (BCNS) is due to mutation in the PTCH gene
located on chromosome 9q22. PTCH gene is the human
homologue of the drosophilia patched gene, negatively reg-
ulating Hedgehog signalling via inhibition of Smoothened
(Smo), a transmembrane protein. Inactivating mutations
of PTCH in BCNS stimulate aberrant Hedgehog signalling
and subsequent BCC development. Sporadic BCCs have
also been shown to contain PTCH mutations in up to
68% of cases. Mutations in tumour suppressor gene p53
cause inactivation of the gene and development of tumours
resistant to apoptosis. Up to 53% of BCCs may have a single
allele mutation of p53 [20]. Skin type is associated with
melanocortin 1 receptor (MC1R) polymorphisms and an
independent risk factor for BCC. Eye colour and tanning
function is associated with polymorphisms in tyrosinase and
subsequent risk of BCC development [21].
Other important risk factors are age over 40, sun bed use,
phototherapy, radiotherapy, male sex, and arsenic exposure
[10]. Immunosuppression confers a 10–100 increased risk
over the general population, a risk which increases with
longer duration of immunosuppression. Fair skin types
(Fitzpatrick skin type I and II) are also at increased risk
of developing BCC, with 19 times reduced risk in darker
skin [14].
3.Diagnosis
Diagnosis is usually clinical. Clinical features are dependent
on the subtype of BCC. Nodular or cystic BCCs present
as raised red, pearly, translucent lesions with peripheral
telangiectasia (Figure 1). Superﬁcial BCC may mimic dis-
coid eczema or Bowen’s disease whilst morphoeic BCC
presents as a subtle scar-like plaque (Figures 2 and 3).
Dermatoscopy may be helpful to identify arborising blood
vessels, ulceration, maple-leaf-like areas characteristic of
BCC [22]. Computer tomography or magnetic resonance
imaging is performed for bony, vascular, or major nerve
invasion. Skin biopsy is performed in the majority of cases
to aid diagnosis and identify subtype of BCC for treatment
planning.
Figure 1: Nodulo-cystic BCC.
Figure 2: Superﬁcial BCC.
Table 1:FactorsassociatedwithhighriskoffutureBCCrecurrence.
High Risk BCC
Aggressive histological subtype; morphoeic, micronodular
Large size >2cm
Perineural, perivascular invasion
Central facial site; periocular, nasal, perioral
Recurrent BCC
4. Treatment
Treatment of BCC is hampered by poor quality, conﬂicting
research with often short-term 1 year clearance data. Most
studies are open, uncontrolled, and retrospective in nature.
The key decision for treatment is identifying high versus low
risk BCC (Table 1). Standard surgical excision and Moh’s
micrographic surgery allows histological conﬁrmation of
tumour clearance and generally remains gold standard for
high risk BCC, whilst the other treatment modalities rely
on clinical observation at followup to conﬁrm treatment
success, with higher recurrence rate at 5-year review.
5.SurgicalExcision
The BCC is excised with a predetermined margin of usually
3-4mm of normal skin to ensure the lesion is fully excised.
The excised tissue is placed in formalin, embedded, and cutJournal of Skin Cancer 3
Figure 3: Morphoeic BCC.
into interrupted vertical sections akin to a “breadloaf” for
histological review. As the entire margin is not examined,
this allows for sampling error and reporting of BCC to be
completely excised when in fact they may not be. In 2004 a
prospective randomised controlled study of surgical excision
versus Mohs’ micrographic surgery by Smeets et al., found
of 199 primary facial BCC excised with 3mm margins, 18%
were incompletely excised at ﬁrst attempt, requiring further
excision [23]. Tumours which were of aggressive histological
subtype were signiﬁcantly more likely to be incompletely
excised initially. 14% had complications, most commonly
wound infection, or necrosis of graft or ﬂap rather than
bleeding or haematoma. Overall recurrence rate of BCC
with surgical excision was 4.1% at 5 year followup. A larger
retrospective review by Rowe et al., of all studies published
since 1947 found a higher recurrence rate of 10.1% at 5-year
followup for standard surgical excision [24].
6. Moh’s Micrographic Surgery
Moh’s micrographic surgery (MMS) was ﬁrst reported in
1941 by Mohs [25]. Excised tissue is frozen and sectioned
horizontally. The entire margin is intraoperatively histologi-
cally examined and further staged excision is performed only
where the tumour is located microscopically. This allows for
greater histological accuracy of complete tumour resection
and increased tissue conservation. In the study by Smeets et
al., comparing surgical excision versus Moh’s micrographic
surgery, 198 patients were randomised to the MMS arm.
Complication rate for MMS was 12%, most commonly
wound infection and ﬂap/ graft necrosis. 5-year recurrence
rate was 2.1%, which was not signiﬁcantly diﬀerent in
comparison to surgical excision (P = .23). Neither was a
signiﬁcantdiﬀerencefoundinpatientperceptionofcosmetic
appearance between MMS and surgical excision for primary
BCC.
However for recurrent facial BCC, MMS is the treatment
of choice. 204 patients with recurrent facial BCC were also
randomised to MMS versus surgical excision. At 5-years
2.4% recurred in the MMS group in comparison to 12.1% in
the surgical group, conﬁrming signiﬁcantly lower recurrence
in the MMS group (P = .015). In addition 30% of tumours
in surgical group were initially incompletely excised and
required further surgery [23]. Similar results were found in
Rowe et al.’s retrospective review of all studies since 1945,
with 1.0% 5-year recurrence for untreated BCC with MMS
and 5.6% 5 year recurrence rates for treatment of recurrent
BCC with MMS [24, 26].
7. Radiotherapy
Radiotherapy (RT) can be eﬀective for primary BCC, recur-
rent BCC or as adjuvant for incompletely excised BCC in
patients where further surgery is neither possible nor appro-
priate. Radiotherapy is a mixture of superﬁcial, electron
beam, and brachytherapy for curved surfaces. Treatment in
fractionsoverseveralvisitsmayproducebettercosmeticout-
comes than a single fraction treatment [10]. Radiotherapy
is contraindicated in radiotherapy recurrent BCC, genetic
syndromes predisposing to skin cancer and connective tissue
disease. Signiﬁcant side eﬀects are radionecrosis, atrophy,
and telangiectasia. Skin cancers can arise from radiotherapy
ﬁeld scars and should be avoided in younger age groups.
A randomised trial of 347 patients compared radiother-
apy versus surgical excision with frozen sections for facial
BCC less than 4cm found signiﬁcantly more recurrence
occurred in the radiotherapy group (7.3%) than the surgical
group (0.7%) at 4-year followup (RR 0.09, 95% CI, 0.01 to
0.69). Cosmetic outcome also signiﬁcantly favoured surgical
excision at 4 years with 87% of patients assessing the surgical
scar as good, compared to 69% after radiotherapy (P<. 01)
[27, 28].
8. Curettage andCautery
Curettage and cautery is one of the commonest tools used
by dermatologists in management of BCC. The tumour is
scraped with a curette and then treated with electrocautery
to control bleeding and destroy any cancer cells at the base
and margin of the wound. The cycle is repeated either once
or twice for increased eﬃcacy. A study of 898 BCC reported
a 5 year cumulative recurrence rate of 6–19%. Recurrence
was higher for central facial areas [29]. A further study of
2314 BCC treated with curettage and cautery also conﬁrmed
signiﬁcantly higher recurrence for facial BCCs [30].
9. Cryotherapy
Cryotherapy is a destructive method of treating BCC
using liquid nitrogen to cause low cell temperature and4 Journal of Skin Cancer
necrosis. Signiﬁcant variation occurs in technique, length,
and number of freeze thaw cycles used. Side-eﬀects include
pain, blistering, infection, and scarring. A nonrandomised
study of 93 patients comparing cryotherapy to radiotherapy,
treated BCC with 2 freeze thaw cycles of freezing for 1
minute, and thaw of 90 seconds. At 2-year followup, in the
cryotherapy group 39% of BCCs had recurred, compared
to 4% in the radiotherapy group. No signiﬁcant diﬀerence
wasfoundinthecosmeticoutcomebetweencryotherapyand
radiotherapy [31]. Another study compared cryotherapy to
surgical excision for head and neck superﬁcial and nodular
BCC, less than 2cm. Cryotherapy was performed using 2
freeze thaw cycles of freezing for 20 seconds, and thaw of 60
seconds. No diﬀerence in recurrence rate was found at 1 year,
but there was a signiﬁcantly better cosmetic outcome with
surgical excision compared to cryotherapy [32].
10. Photodynamic Therapy
Photodynamic therapy (PDT) is performed by topical
application of the prodrug 5-aminolaevulinic acid (ALA) or
methyl aminolaevulinic (MAL) to the BCC. The prodrug
is converted intracellularly into protoporphyrin IX (PpIX)
via the heme pathway. The BCC is then irradiated with
a light source and in the presence of oxygen, a cytotoxic
reaction occurs within the target cells where the PpIX has
accumulated. The light source is usually either 410nm blue
light or 630nm red light to match the absorption peak for
PpIX.Redlightmaybepreferredwiththelipophilic MALfor
deeper tissue penetration. Superﬁcial BCC has been shown
to achieve 87% clearance, and better cosmesis than with
curettage or cryotherapy [33].
For nodular BCC a study comparing MAL PDT with
surgical excision in 101 patients showed a MAL PDT cure
rate of 76% compared to 96% for surgical excision. Cosmesis
was better for PDT with 87% of patients rated as good
cosmetic outcome in comparison to 54% for surgery [34].
11. Imiquimod
Imiquimod is an immune response modiﬁer, binding to cell
surface toll receptor 7 and/or 8. Binding activates proinﬂam-
matory cytokine production and subsequent cytotoxic T cell
mediatedcelldeath.Studiesoftopicaladministrationforlow
risk BCC at least 5 days per week conﬁrmed 81% histological
c l e a r a n c ea tw e e k6o r1 2[ 35–37]. A further study of topical
imiquimod applied 5 days per week for a total of 6 week in
182 patients found 69% remained clinically clear at a 5 year
followup period [38]. Side eﬀects included application site
erythema, crusting, erosion, and pain.
12. Conclusion
Research has improved our understanding of the patho-
genesis of basal cell carcinoma, and with this has arrived
several new generation nonsurgical treatments. However
Moh’s micrographic surgery remains gold standard for high
risk BCC. Choice of treatment for basal cell carcinoma
is complex and must take into account tumour type,
location, cosmesis, recurrence, comorbidity and patient
preference.
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